PHARMACEUTICAL COMBINATION CONTAINING TNO155 AND RIBOCICLIB Russian patent published in 2024 - IPC A61K31/497 A61K31/519 A61P35/00 

FIELD: medicine; oncology.

SUBSTANCE: invention discloses a method of treating cancer, including administering to a subject in need of it a pharmaceutical composition containing (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the second the therapeutic agent is a CDK4/6 inhibitor such as 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from oesophageal or head and neck squamous cell carcinoma, colorectal cancer, ovarian cancer, pancreatic cancer or non-small cell lung cancer and renal cell carcinoma and wherein 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide or a pharmaceutically acceptable salt thereof is administered orally at a dose of 200 mg per day, 300 mg per day, 400 mg per day, 500 mg per day or 600 mg per day, and where (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine or a pharmaceutically acceptable salt thereof is administered orally at a dose of 20 mg per day, or 30 mg per day, or 40 mg per day, or 50 mg per day, or 60 mg per day.

EFFECT: increased effectiveness compared to one single agent in the treatment of squamous cell carcinoma of the oesophagus or head and neck, colorectal cancer, ovarian cancer, pancreatic cancer or non-small cell lung cancer and renal cell carcinoma.

6 cl, 4 dwg, 5 ex